An additional phase I clinical trial [108] combined a MVA virus-based vaccine expressing wild-type p53 transgene with pembrolizumab in 11 patients with advanced solid cancers, including one patient with HNSCC. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.